Molecular Docking Studies of Glabrene and Human Epidermal Growth Factor Receptor Kinase
Background: Human epidermal growth factor receptor 2 (Her2) gene located in human chromosome17, encodes Her2 tyrosine kinase protein, and is overexpressed in breast cancer cells. Her2 is activated on phosphorylation of tyrosine by adenosine triphosphate (ATP). Nonetheless, Her2 excessively partakes in the development and prognosis of specific types of aggressive breast cancers. Therefore, Her2 inhibition therapy is primary target for the treatment of aggressive breast cancer. At present, lapatinib is one of the Food and Drug Administration approved Her2 inhibitors used in cancer therapy. In molecular docking process, glabrene with slightly higher binding energy competitively bound to the active receptor site comparable to lapatinib and ATP. Therefore, glabrene could emerge as a potential candidate for restricting Her2 overexpressed breast cancer.
Objective: The present study aimed to demonstrate the inhibitory activity of glabrene, an isoflavene and xenoestrogen found in liquorice root, along with known Her2 inhibitor, lapatinib.
Methods: ATP, lapatinib, and glabrene were docked on human Her2 protein 3D structure which revealed glabrene as a competitive Her2 inhibitor akin to lapatinib. Results: The docking results suggested the binding site similarities of ATP, lapatinib, and glabrene. The binding energies of docked ATP, lapatinib, and glabrene complexes with Her2 were −9.1 kcal/mol, −10.5 kcal/mol, and −11.3 kcal/mol, respectively.
Conclusion: The in silico docking simulation of ATP, lapatinib, and glabrene suggested that glabrene is likewise a competitive Her2 inhibitor.
Scroeder, R.L.; Stevens, C.L.; Sridhar, J. Review: Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer. J. Mol., 2014, 19, 15196–15212.
Berger, M.; Mendrola, J.M.; Lemmon, M.A. EebB3/HER3 does not Homodimerize Upon Neuregulin Binding at the Cell Surface. FEBS Lett., 2004, 568(1-3), 332–6.
Moasser, M.M. Targeting the Function of the HER2 Oncogene in Human Cancer Therapeutics. Oncogene, 2007, 26(46), 6577–99.
Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W.T.; Clarkson, B.; Kuriyan, J. Structural Mechanism for STI[1]571 Inhibition of Abelson Tyrosine Kinase. Science, 2000, 289(5486), 1938–42.
Arkin, M.; Moasser, M.M. HER2 Directed Small Molecule Antagonists. Curr. Opin. Investig. Drugs, 2008, 9(12), 1264–76.
Mitri, Z.; Constantine, T.; O’Regan, R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother. Res. Pract., 2012, 2012, 743193.
Iqbal, N.; Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Implications. Mol. Biol. Int., 2014, 2014, 852748.
Brandt-Rauf, P.W.; Pincus, M.R.; Carney, W.P. The c-erbB-2 Protein in Oncogenes Is: Molecular Structure to Molecular Epidemiology. Crit. Rev. Oncogenesis., 1994, 5(2-3), 313–29.
Bartolomeusz, C.; Gonzalez-Angulo, A.M. Targeting the PI3K Signaling Pathway in Cancer Therapy. Expert Opin. Ther. Targets., 2012, 16(1), 121–30.
Xia, W.; Mullin, R.J.; Keit, B.R.; Liu, L.H.; Ma, H.; Rusnak, D.W.; Owens, G.; Alligood, K.J.; Spector, N.L. Antitumor Activity of GW572016: A Dual Tyrosine Kinase Inhibitor Blocks EGF Activation of EGFR/ErbB2 and Downstream ERK1/2 and Akt Patways. Oncogene. 2002, 21(41), 6255–63.
OSIRIS Property Explorer. Available from: https://www. organiccemistry.org/prog/peo [Last accessed on 2021 Jun 20].
Tamir, S.; Eizenberg, M.; Somjen, D.; Izrael, S.; Vaya, J. Estrogen-like activity of glabrene and other constituents isolated from licorice root. J. Steroid Bioch. Mol. Biol., 2001, 78(3), 291–8.
Mitscher, L.A.; Drake, S.; Gollapudi, S.R.; Harris, J.A.; Sankel, D.M. Isolation and Identification of Igher Plant Agents Active in Antimutagenic Assay Systems: Glycyrrhiza glabra. Basic Life Sci., 1986, 39, 153–65.
Somjen, D.; Knoll, E.; Vaya, J.; Stern, N.; Tamir, S. Estrogen-like Activity of Licorice Root Constituents: Glabridin and Glabrene, in Vascular Tissues In Vitro and In Vivo. J. Steroid. Bioch. Mol. Biol., 2004, 91, 147–55.
Somjena, D.; Katzburg, S.; Vaya, J.; Kayec, A.M.; David Hendel, D.; Posner, G.; Tamir, S. ESTROGENIC activity of Glabridin and Glabrene from Licorice Roots on Human Osteoblasts and Prepubertal Rat Skeletal Tissues. J. Steroid. Bioch. Mol. Biol., 2004, 91, 241–6.
Powers, C.N.; Setzemr, W.N. A Molecular Docking Study of Phytochemical Estrogen Mimics from Dietary Herbal Supplements. In Silico Pharmacol., 2015, 3(4), 1–63.
Nerya, O.; Vaya, J.; Musa, R.,; Izrael, S.; Ben-Arie, R.; Pamir, S. Glabrene and Isoliquiritigenin as Tyrosinase Inibitors from Licorice Roots. J. Agric. Food Chem., 2003, 51(5), 1201–7.
Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Deliv Rev., 2001, 46, 3–26.
Dubey, K.; Dubei, R.; Gupta, R.G.A. In-Silico Reverse Docking Studies for the Identification of Potential of Betanin on Some Proteins Involved in Diabetes and its Complications. J. Drug Deliv. Ther., 2019, 9, 72–74.
Trott, O.; Olson, A.J. AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Drug Scoring Function. J. Comput. Chem. 2010, 31, 455–61.
Dallakyan, S.; Olson, A.J. Small-Molecule Library Screening by Docking with PyRx. Chemical Biology (Springer), 2015, 1263, 243–50.
Devaurs, D.; Bouard, L.; Vaisset, M.; Zanon, C.; Al-Bluwi, I.; Iehl, R.; Simeon, T.; Cortes, J. MoMA-LigPath: A Web Server to Simulate Protein-ligand Unbinding. Nucleic Acids Res., 2013, 41(W1), W297–302.
Cortes, J.; Le, D.T.; Iehl, R.; Simeon, T. Simulating Ligand[1]induced Conformational Changes in Proteins Using a Mechanical Disassembly Method. Phys. Chem. Chem. Phys. 2010, 12(29), 8268–76.
Lopez-Blanco, J.R.; Aliaga, J.L.; Quintana-Orti, E.S.; Chacon, P. iMODS: Internal Coordinates Normal Mode Analysis Server. Nucleic Acids Res., 2014, 42, W271–76.
Lopez-Blanco, J.R.; Garzon, J.I.; Chacon, P. iMod: Multipurpose Normal Mode Analysis in Internal Coordinates. Bioinformatics. 2011, 27, 2843–50.
Kovacs, J.A.; Chaco, P.; Abagyan, R. Predictions of Protein Flexibility: First-Order Measures. Proteins. 2004, 56, 661–8.
Frankel, C.; Palmieri, F.M. Lapatinib Side-effect Management. Clin. J. Oncol. Nurs. 2010, 14(2), 223–33.
Choi, H.D.; Chang, M.J. Cardiac Toxicities of Lapatinib in Patients with Breast Cancer and other HER2 Positive Cancers: A Meta[1]analysis. Breast Cancer Res Treat. 2017, 166, 927–936.
Chen, D.; Oezguen, N.; Urvil, P.; Ferguson, C.; Dann, S.M.; Savidge, T.C. Regulation of Protein-ligand Binding Affinity by Hydrogen Bond Pairing. Sci. Adv., 2016, 2(3), e1501240.
Jamal, M.S.; Parveen, S.; Veg, M.A.; Suhail, M. Chaudary, A.G.A.; Damanhouri, G.A.; Abuzenadah, A.M.; Rehan, M. Anticancer Compound Plumbagin and its Molecular Targets: A Structural Insight into the Inhibitory Mechanisms Using Computational Approaches. PLoS One, 2014, 9(2), e87309.